Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Blueprint Medicines Corp Market Cap
The Blueprint Medicines Corp (BPMC) share price is expected to increase by 30.3% over the next year. This is based on calculating the average 12-month share price estimate provided by 20 stock analysts who have covered BPMC. Price targets range from $81 at the low end to $167 at the high end. The current analyst consensus for BPMC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 20 Wall Street analysts have assigned BPMC 14 buy ratings, 5 hold ratings, and 1 sell ratings. This means that analysts expect Blueprint Medicines Corp to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BPMC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BPMC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Reni Benjamin JMP Securities | Market Outperform | $125 | Reiterates | Nov 18, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $135 | Reiterates | Nov 15, 2024 |
| Ami Fadia Needham | Buy | $135 | Reiterates | Nov 15, 2024 |
| Brian Cheng JP Morgan | Overweight | $126 | Initiates | Nov 14, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $135 | Reiterates | Oct 31, 2024 |
| Derek Archila Wells Fargo | Overweight | $151 | Maintains | Oct 31, 2024 |
| Ami Fadia Needham | Buy | $135 | Maintains | Oct 31, 2024 |
| Ami Fadia Needham | Buy | $133 | Reiterates | Oct 30, 2024 |
| David Dai UBS | Neutral | $88 | Initiates | Oct 24, 2024 |
| Ami Fadia Needham | Buy | $133 | Maintains | Aug 5, 2024 |
| Michael Schmitz Guggenheim | Buy | $138 | Maintains | Aug 2, 2024 |
| Joel Beatty Baird | Outperform | $127 | Maintains | Aug 2, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Aug 1, 2024 |
| Peter Lawson Barclays | Equal-Weight | $105 | Maintains | Jul 29, 2024 |
| Michael Ulz Morgan Stanley | Equal-Weight | $115 | Maintains | Jul 12, 2024 |
| Matthew Biegler Oppenheimer | Outperform | $125 | Maintains | Jul 8, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Jun 28, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $125 | Reiterates | Jun 7, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $140 | Initiates | May 14, 2024 |
| Andrew Berens Leerink Partners | Market Perform | $97 | Upgrade | May 6, 2024 |
When did it IPO
2015
Staff Count
638
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Kathryn Haviland M.B.A.
Market Cap
$6.12B
In 2023, BPMC generated $249.4M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BPMC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 14 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - JP Morgan has begun coverage of Blueprint Medicines Corporation (BPMC), a biotech firm specializing in immune mast cell modulation.
Why It Matters - JP Morgan's coverage initiation on Blueprint Medicines signals potential interest and investment credibility, which could influence stock performance and investor sentiment in the biotech sector.
Fri, 15 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Blueprint Medicines' AYVAKIT shows strong market adoption in systemic mastocytosis and gastrointestinal stromal tumors, with recent expansion in Germany and promising investigational drugs enhancing growth potential.
Why It Matters - Blueprint Medicines' revenue growth from AYVAKIT and its expansion into new markets signal strong demand, impacting future earnings. An active pipeline suggests sustained growth and potential stock appreciation.
Thu, 31 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Blueprint stock rises after strong Q3 results, fueled by significant Ayvakit sales growth. The company also increases its 2024 revenue guidance.
Why It Matters - Strong Q3 results and increased revenue guidance for 2024 indicate positive growth prospects, potentially boosting investor confidence and stock performance in Blueprint.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Blueprint Medicines Corporation (NASDAQ:BPMC) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 8:00 AM ET, featuring key company executives and financial analysts.
Why It Matters - The upcoming earnings call on October 30 will provide insights into Blueprint Medicines' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Blueprint Medicines reported $128.2 million in AYVAKIT net revenues for Q3 2024 and raised its 2024 revenue guidance to $475-$480 million. They plan to start the HARBOR Part 2 study by year-end.
Why It Matters - Strong AYVAKIT revenue growth and raised guidance signal robust demand, potentially increasing investor confidence and driving stock value. Upcoming study initiation may further enhance prospects.
Wed, 30 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Blueprint Medicines (BPMC) reported a quarterly loss of $0.89 per share, better than the expected loss of $0.97, and improved from a loss of $2.20 per share a year prior.
Why It Matters - Blueprint Medicines' smaller-than-expected quarterly loss signals potential improvement in financial performance, which may boost investor confidence and affect stock valuation positively.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
